publication . Article . 2020

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

Simon G. P. Funnell; W. E. Dowling; César Muñoz-Fontela; Pierre Stéphane Gsell; Donald E. Ingber; G. A. Hamilton; Leen Delang; Joana Rocha-Pereira; Suzanne J. F. Kaptein; K. H. Dallmeier; ...
Open Access English
  • Published: 26 Aug 2020 Journal: Nature Communications, volume 11 (eissn: 2041-1723, Copyright policy)
  • Publisher: Nature Publishing Group UK
Abstract
International audience; There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collaborative effort of independent researchers who have recently all come to the same conclusion—that chloroquine or hydroxchloroquine are unlikely to provide clinical benefit against COVID-19.
Persistent Identifiers
Subjects
free text keywords: Comment, Animal disease models, Respiratory system models, SARS-CoV-2, Preclinical research, General Physics and Astronomy, General Biochemistry, Genetics and Molecular Biology, General Chemistry, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Science, Q, Coronavirus disease 2019 (COVID-19), MEDLINE, Medicine, business.industry, business, Pandemic, Repurposing, Population, education.field_of_study, education, Chloroquine, medicine.drug, Betacoronavirus, biology.organism_classification, biology, Hydroxychloroquine, Intensive care medicine, medicine.medical_specialty, lcsh:Science, lcsh:Q
Funded by
EC| EVAg
Project
EVAg
European Virus Archive goes global
  • Funder: European Commission (EC)
  • Project Code: 653316
  • Funding stream: H2020 | RIA
,
ANR| IDMIT
Project
IDMIT
Infrastructure nationale pour la modélisation des maladies infectieuses humaines
  • Funder: French National Research Agency (ANR) (ANR)
  • Project Code: ANR-11-INBS-0008
,
NIH| Lung-on-a-Chip Disease Models for Efficacy Testing
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1UG3HL141797-01
  • Funding stream: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
,
EC| TRANSVAC2
Project
TRANSVAC2
European Vaccine Research and Development Infrastructure
  • Funder: European Commission (EC)
  • Project Code: 730964
  • Funding stream: H2020 | RIA
Communities
Instruct-ERICInstruct-ERIC Projects: European Vaccine Research and Development Infrastructure
COVID-19

1. Osada, N. et al. The genome landscape of the african green monkey kidneyderived vero cell line. DNA Res. 2014 21, 673-683 (2014).

2. Benam, K. H. et al. Small airway on a chip enables analysis of human lung inflammation and therapeutic responses in vivo. Nat. Methods 13, 151-157 (2016).

3. Benam, K. H. et al. Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip. Cell Syst. 3, 456-466 (2016).

4. Nicolas de Lamballerie, C. et al. Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia. Sci. Rep. 9, 11493 (2019).

5. Si, L. et al. Human organs-on-chips as tools for repurposing approved drugs as potential influenzae and COVID-19 therapeutics in viral pandemics. https://doi.org/10.1101/2020.04.13.039917 (2020).

6. Maisonnasse, P. et al. Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non-human primates. Nature https://doi.org/ 10.21203/rs.3.rs-27223/v1 (2020).

7. Weston, S. A. et al. Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. https://doi.org/10.1101/ 2020.03.25.008482 (2020).

8. Chan, J. F. et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa325 (2020).

9. Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in Golden hamsters. Nature https://doi.org/10.1038/s41586-020-2342-5 (2020).

10. Kaptein, S. J. F. et al. Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine. https://doi.org/10.1101/2020.06.19.159053 (2020).

11. Rosenke, K. et al. Hydroxychloroquine proves ineffective in Hamsters and Macaques infected with SARS-CoV-2. https://doi.org/10.1101/ 2020.06.10.145144 (2020).

12. Munster, V. J. et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature https://doi.org/10.1038/s41586-020-2324-7 (2020).

13. Huh, K. et al. Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea. https://doi.org/10.1101/ 2020.05.04.20089904 (2002).

Any information missing or wrong?Report an Issue